TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv 105 84 50 35 29 18 TRAB/2FTRAB/2O + - + - GFs B M.W. None=0<1% =11-10% =2 10-33%

Slides:

Advertisements

Similar presentations

Hereditary ovarian/breast cancers (HOC/HBOC) Chair and Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents. Head: Prof.

Advertisements

Ji Young Lee, MD, PhD, David Marchetti, MD, M Steven Piver, MD Department of Obstetrics and Gynecology Sisters of Charity Hospital, Buffalo, NY The Clinical.

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

Genetic and Molecular Epidemiology

Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”

Ct value Log concentration miR-375 miR-221 Supplementary Figure S1.

Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero,

4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:

Vitamin D Deficiency is Common at Breast Cancer Diagnosis and is Associated with a Significantly Higher Risk of Distant Recurrence and Death in a Prospective.

Comparing the Positive Effect of Vitamin E and Flouxetine in the Treatment of Hot Flashes in Breast Cancer Patients. Comparing the Positive Effect of.

Lymphadenectomy in Epithelial Ovarian Cancer

Management and Development for Health (MDH)

Black Patients Die Earlier after Surgery for Esophageal Cancer Andrea S. Wolf, MD, MPH, Emanuela Taioli MD, PhD, Marlene Camacho-Rivera, ScD, MPH, Andrew.

PANCREATIC CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY 2009.

Romero IL, McCormick A, McEwen et al Obstetrics & Gynecology, vol. 119:61-67.

Tumors Dr. N. Salmo. Adrenal cortical tumor. Describe it grossly. Benign or Malignant??

Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.

Investigation of CA9 expression in pulmonary metastatic lesions from patients with clear cell renal cell carcinoma Pierre Tennstedt 1, Peter Schneider.

Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.

Supplementary table 1 Supplementary table 1. Clinical-pathological features of the resection-only and chemotherapy/resection stage II/III colorectal cancer.

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

Dr. Saadeh Jaber OBGYN consultant Epidemiology Second most common gynecological cancer. >35, median 70 It accounts for deaths more than cancer of.

17 th century microscopes In The Name of God PARISA REZAEI,M.D.,AP.CP.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.

Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.

Supplementary Table S1. Patient demographics of the RRBS discovery set. Characteristics RRBS discovery set TotalIDH1/2 WT IDH1 MUT No. of Patients

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

Postmenopausal breast cancer patients included in the original Stockholm tamoxifen trial (n=2459) Stockholm 2 cohort (n=679) Stockholm 3 cohort (n=1780)

GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.

ANALYTIC LUNG CANCER by CLASS N = 351 Class 0: Dx’d at JHH only 1: Dx’d at JHH and received all/part of 1st course tx at JHH 2: Dx’d at an outside facility.

14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.

Wilms’ tumour gene 1 (WT1) is a new prognostic marker in high grade uterine sarcoma A. Coosemans, B. Van Calster, L. Verbist, Ph. Moerman, I. Vergote,

Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.

Premature deaths due to Prostate Cancer: The Role of Diagnosis and Treatment Appathurai Balamurugan MD, MPH S William Ross MD Chris Fisher, BS Jim Files,

: 1.Introduction The cold shock “Y-box binding protein-1” (YB-1) has an important role in regulation of cellular proliferation and differentiation. Overexpression.

Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,

Randomized Phase III Study Of Gemcitabine

AOC Surgical Outcome Survey

Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues

Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.

Prognostic significance of tumor subtypes in male breast cancer:

San Antonio Breast Cancer Symposium - December 6-10, 2011 Pre-operative haematological markers and prognosis in early breast cancer Cordiner RL1, Mansell.

Lung squamous cell carcinoma

Copyright © 2009 American Medical Association. All rights reserved.

Picture 3. Higher grade tumors are more frequently Ki67 positive

Hallett, et al., - Supplementary Figure 1

EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,

Figure S1. DCYTB expression is higher in ER+ than ER- patients

Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:

سرطان الثدي Breast Cancer

4155 primary hepatocellular carcinoma with known diagnosis month/year

Volume 148, Issue 1, Pages (January 2018)

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

ADAM8 is overexpressed in human breast cancer AADAM8 mRNA expression in samples from breast tumor and normal breast tissue was analyzed using the Oncomine.

GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

HRs for prostate cancer by medication status.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

LINC00092 binds with PFKFB2 to promote ovarian cancer metastasis.

Supplementary Figure S5

South Carolina Statewide Cancer Prevention & Control Program

Supplemental Material

Volume 20, Issue 8, Pages (August 2019)

median of follow-up (month)

Presentation transcript:

TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv TRAB/2FTRAB/2O GFs B M.W. None=0<1% =11-10% = % = % =533-66% =4 Negative=0Low=1 Medium=2High=3 Frequency of Elafin-Positive Cells Staining Intensity of Elafin-Positive Cells C D

B Basal-like HER2+ Luminal A Luminal B Normal TCGA Breast p= p< Log 2 -mean centered values PAM50 Normal Luminal B Luminal A Basal HER2 PI3 (Elafin) TCGA Breast Supplemental Figure 2A -2 2 Log 2 -Median Centered

FactorsElafin Negative (n=171)Positive (n=42)p-value Age at diagnosis, year 0.09 Mean Median (range)58 (20-83)63 (27-87) Histological Type 0.7 Serous125 (73.1)32 (76.2) Endometroid19 (11.1)2 (4.8) Clear Cell8 (4.7)1 (2.4) Transitional Cell4 (2.3)2 (4.8) Malignant Mixed Müllerian7 (4.0)1 (2.4) Undifferentiated7 (4.0)2 (4.8) Others1 (0.6)2 (4.8) FIGO stage I/II33 (19.3)3 (7.2) III/IV138 (80.8)39 (92.8) Grade 0.5 Low15 (8.8)2 (4.8) High156 (91.2)40 (95.2) Ascites Level 0.05 No18 (15)1 (2.5) Yes102 (85)39 (97.5) Unknown512 Response to treatment 0.02 No24 (15)12 (30.8) Yes136 (85)27 (69.2) Unknown113 Serum CA 125 level <500 U/mL43 (45.3)6 (20) >500 U/mL52 (54.7)24 (80) Unknown7612 Univariate analysis ovarian cancer (n=213) Supplemental Table 1 Factor HRSeP95% CI Stage I/IIReferent III/IV Elafin Positive Ascites Response to treatment < Multivariate Cox Proportional Hazards Analysis of Clinicopathologic Variables’ Influence on Ovarian Cancer Disease-Specific Survival (DSS) in whole cohort (n=213) A B